Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

Rhea-AI Summary

Mesoblast (Nasdaq: MESO) appointed Dr. Teresa Montagut as Head of Clinical Development and Medical Affairs, effective March 11, 2026. She will report to the Chief Medical Officer and lead medical affairs, investigator-initiated trials, clinical collaborations, and communications to advance cell therapy programs.

Dr. Montagut joins from Regeneron with prior roles at Novartis, Genentech, and Atara; she will support expansion of the FDA-approved product Ryoncil into pediatric and adult inflammatory indications.

Positive

• Appointment of Teresa Montagut effective March 11, 2026
• Mandate to lead medical affairs and investigator-initiated trials
• Experience from Regeneron, Novartis, Genentech and Atara

Negative

• None.

News Market Reaction – MESO

-3.58%

1 alert

-3.58% News Effect

On the day this news was published, MESO declined 3.58%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $14.55 Vol: Volume 90,983 is at 0.32x...

low vol

$14.55 Last Close

Volume Volume 90,983 is at 0.32x the 20-day average of 282,048, indicating light trading before this news. low

Technical Shares at $15.63 are trading slightly below the 200-day MA of $15.64 and 27.3% under the 52-week high.

Peers on Argus

MESO was down 0.7% while most close biotech peers were up (e.g., DYN +1.22%, AUP...

MESO was down 0.7% while most close biotech peers were up (e.g., DYN +1.22%, AUPH +0.75%, HRMY +0.52%), with IMCR the main decliner at -2.28%, pointing to stock-specific factors rather than a sector move.

Previous Clinical trial Reports

1 past event · Latest: Jul 21 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Jul 21	Phase 3 enrollment start	Positive	+4.4%	Started 300-patient confirmatory Phase 3 CLBP trial for rexlemestrocel-L.

Pattern Detected

Limited but prior clinical-trial news saw a positive share-price reaction.

Recent Company History

This announcement adds leadership depth in clinical development and medical affairs as Mesoblast advances multiple cell therapy programs. A prior July 21, 2024 update on commencing a confirmatory Phase 3 trial of rexlemestrocel-L for chronic low back pain, involving 300 patients with a 12‑month pain endpoint, coincided with a 4.43% gain. Together, these events underscore continued focus on translating Mesoblast’s pipeline into late-stage trials and potential label expansions.

Historical Comparison

+4.4% avg move · Past clinical-trial updates averaged a 4.43% move. This leadership-focused clinical news fits Mesobl...

clinical trial

+4.4%

Average Historical Move clinical trial

Past clinical-trial updates averaged a 4.43% move. This leadership-focused clinical news fits Mesoblast’s pattern of advancing late-stage cell therapy programs.

Historical clinical news highlights progression of rexlemestrocel-L into a confirmatory Phase 3 CLBP trial; today’s appointment supports execution and expansion of these and future studies.

Market Pulse Summary

This announcement strengthens Mesoblast’s clinical development and medical affairs leadership as it ...

Analysis

This announcement strengthens Mesoblast’s clinical development and medical affairs leadership as it seeks to expand Ryoncil® and advance its cell therapy pipeline in pediatric and adult inflammatory conditions. In the past, similar clinical-trial milestones, such as the July 21, 2024 Phase 3 CLBP enrollment update involving 300 patients, have been important markers of progress. Investors may watch for future trial initiations, enrollment updates, and label-expansion efforts stemming from this appointment.

Key Terms

allogeneic, cell therapy, oncology, immunotherapy, +4 more

8 terms

allogeneic medical

"global leader in allogeneic cellular medicines for inflammatory diseases"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

cell therapy medical

"unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

oncology medical

"Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

immunotherapy medical

"She previously led multiple cancer immunotherapy programs across Novartis, Genentech"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

gastrointestinal medical

"Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary"

Gastrointestinal describes the stomach and intestines and the processes that break down food and absorb nutrients — think of it as the body’s food‑processing and waste‑handling system. For investors, gastrointestinal matters because drugs, devices, or illnesses that affect this system can drive clinical trial outcomes, regulatory decisions, treatment demand and safety concerns, all of which can materially influence revenue, costs and risk for healthcare companies.

genitourinary medical

"Investigator Sponsored Studies in gastrointestinal and genitourinary areas."

The genitourinary system is the body’s combined organs for reproduction and waste removal — essentially the plumbing that includes kidneys, bladder, ureters, urethra and reproductive organs. Investors care because drugs, devices or procedures targeting this system address common, often chronic conditions (like kidney disease, urinary incontinence or prostate issues), which can create sizable, steady markets and predictable revenue streams for healthcare companies.

tumor immunology medical

"her PhD in Tumor Immunology from Memorial Sloan Kettering Cancer Center"

Tumor immunology is the study of how the body's immune system recognizes, responds to, and sometimes fails to stop cancer cells, and how those interactions can be changed to fight tumors. It matters to investors because advances in this field underpin new treatments that can transform patient outcomes and create major revenue streams or reshape companies’ drug pipelines, much like upgrading a building’s security system to detect and remove intruders.

investigator-initiated trials technical

"fostering clinical collaborations and spearheading investigator-initiated trials, enhancing"

Clinical studies designed and run by independent physicians or academic researchers rather than by a drug or device company; the investigator shapes the question, protocol and oversight and may use an existing therapy or a company’s product with permission. For investors, these trials can reveal new uses, safety signals or early effectiveness at relatively low cost to companies, like a third-party test drive that can boost or dim a product’s commercial prospects and affect development timelines and valuation.

AI-generated analysis. Not financial advice.

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical Affairs reporting to the Chief Medical Officer Dr. Eric Rose. In this role, Teresa will lead Mesoblast’s medical affairs organization, fostering clinical collaborations and spearheading investigator-initiated trials, enhancing clinical and medical communications, and engaging with healthcare professionals. She will play a critical role in unlocking the value of Mesoblast's cell therapy programs in new pediatric and adult inflammatory conditions in partnership with investigators and key opinion leaders.

Teresa brings extensive experience in medical leadership and pharmaceutical development, with a strong background in translating clinical science into meaningful patient outcomes. Teresa joined Mesoblast from Regeneron where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. She previously led multiple cancer immunotherapy programs across Novartis, Genentech, and Atara Biotherapeutics.

Teresa earned her MD from Universidad Nacional Autónomade México and her PhD in Tumor Immunology from Memorial Sloan Kettering Cancer Center/Cornell University. She completed fellowships at Massachusetts General Hospital, Howard Hughes Medical Institute, and Rockefeller University. Teresa also serves on the Board of Directors of the Global Pediatric Alliance, supporting maternal and pediatric healthcare in under-served indigenous communities in Latin America, particularly Mexico.

“Teri’s commitment to scientific excellence and her expertise in investigator-initiated clinical trial execution is central to successful implementation of our strategy to expand the range of indications of our FDA approved product Ryoncil^® in pediatric and adult inflammatory conditions, as well as advancing our pipeline of transformative cellular therapies,” said Dr. Silviu Itescu, Chief Executive Officer of Mesoblast.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Rubenstein	BlueDot Media
Caroline Nelson	Steve Dabkowski
T: +1 703 489 3037	T: +61 419 880 486
E: cnelson@rubenstein.com	E: steve@bluedot.net.au

FAQ

Who is Teresa Montagut and what role did Mesoblast (MESO) assign her on March 11, 2026?

She is Mesoblast's new Head of Clinical Development and Medical Affairs, reporting to the CMO. According to the company, she will lead medical affairs, clinical collaborations, and investigator-initiated trials to support clinical programs.

How will Dr. Teresa Montagut's appointment affect Mesoblast's plans for Ryoncil (MESO)?

Her role targets expanding Ryoncil into pediatric and adult inflammatory indications. According to the company, she will work with investigators and key opinion leaders to unlock additional clinical value for Ryoncil.

What relevant industry experience does Teresa Montagut bring to Mesoblast (MESO)?

She brings leadership in early pipeline and investigator-sponsored studies from Regeneron and prior program leadership at Novartis, Genentech, and Atara. According to the company, this includes cancer immunotherapy and medical affairs expertise.

To whom does Teresa Montagut report at Mesoblast (MESO) and what will she oversee?

She reports to the Chief Medical Officer, Dr. Eric Rose, and will oversee medical affairs, clinical communications, and investigator-initiated trials. According to the company, she will foster clinical collaborations with healthcare professionals.

Does Teresa Montagut have academic or clinical training relevant to Mesoblast's pipeline (MESO)?

Yes; she holds an MD and a PhD in Tumor Immunology and completed fellowships at major research institutions. According to the company, her training includes Memorial Sloan Kettering, Mass General, and Rockefeller University.

Will Teresa Montagut engage with external investigators and pediatric initiatives at Mesoblast (MESO)?

Yes; her remit includes engaging investigators and key opinion leaders to advance pediatric programs. According to the company, she also serves on the Global Pediatric Alliance board supporting maternal and pediatric healthcare in Latin America.